Iterum Therapeutics plc (ITRMF): Nasdaq/NYSE listing notice — Iterum Therapeutics notified of non-compliance with Nasdaq $1.00 bid price rule; 180-day cure period to March 2024

Iterum Therapeutics plc

Received deficiency notice on Sep 26, 2023 after 30 consecutive business days of closing bid price below $1.00.
Must regain compliance by March 25, 2024 by achieving $1.00 close for at least 10 consecutive business days.
May be eligible for additional 180-day cure period if meeting other Nasdaq listing standards and providing written intent to cure.
Company will consider all options, including a potential reverse share split, to address the deficiency.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Iterum Therapeutics plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

September 26, 2023, Iterum Therapeutics plc (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC, (“ Nasdaq ”) indicating that, based on the closing bid price for the last 30 consecutive business days, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company maintain a minimum bid price of $1.00 per share (the “ Bid Price Rule ”) for continued listing on The Nasdaq Capital Market. The Notice does not result in the immediate delisting of the Company’s ordinary shares from The Nasda

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Iterum Therapeutics plc filing history →

Source: SEC EDGAR

accession 0000950170-23-050856

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.